Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID‐19, when compared with an active comparator. We performed a propensity‐score‐matched cohort study with active...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Sainsbury, Christopher, Wang, Jingya, Gokhale, Krishna, Acosta‐Mena, Dionisio, Dhalla, Samir, Byne, Nathan, Chandan, Joht Singh, Anand, Astha, Cooper, Jennifer, Okoth, Kelvin, Subramanian, Anuradhaa, Bangash, Mansoor N., Taverner, Thomas, Hanif, Wasim, Ghosh, Sandip, Narendran, Parth, Cheng, Kar K., Marshall, Tom, Gkoutos, Georgios, Toulis, Konstantinos, Thomas, Neil, Tahrani, Abd, Adderley, Nicola J., Haroon, Shamil, Nirantharakumar, Krishnarajah
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2020
Soggetti:
Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7537530/
https://ncbi.nlm.nih.gov/pubmed/32991065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14203
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi